Rink et al. reviewed the literature on the utility of circulating biomarkers, such as circulating tumor DNA (ctDNA) in plasma and urine samples in NMIBC patients, and suggested the use of biomarkers (e.g., the detection of FGFR3 and PIK3CA mutations in plasma and urine and the methylation levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 in urine specimens) for disease surveillance in the future [45]. Here, FGFR3 is linked to neoplasm.